Plasmodium falciparum Plasmepsin 2 Duplications, West Africa

被引：21

作者：

Inoue, Juliana ^{[1
]}

Silva, Miguel ^{[2
]}

Fofana, Bakary ^{[3
]}

Sanogo, Kassim ^{[3
]}

Martensson, Andreas ^{[1
]}

Sagara, Issaka ^{[3
]}

Bjorkman, Anders ^{[4
]}

Veiga, Maria Isabel ^{[2
]}

Ferreira, Pedro Eduardo ^{[2
]}

Djimde, Abdoulaye ^{[3
]}

Gil, Jose Pedro ^{[1
,4
,5
]}

机构：

[1] Uppsala Univ, Uppsala, Sweden

[2] Univ Minho, Braga, Portugal

[3] Univ Sci Tech & Technol Bamako, Bamako, Mali

[4] Karolinska Inst, Stockholm, Sweden

[5] Univ Lisbon, Lisbon, Portugal

来源：

EMERGING INFECTIOUS DISEASES | 2018年 / 24卷 / 08期

基金：

瑞典研究理事会;

关键词：

DIHYDROARTEMISININ-PIPERAQUINE; MALARIA; ASSOCIATION; EFFICACY; MALI;

D O I：

10.3201/eid2408.180370

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Dihydroartemisinin/piperaquine (DHA/PPQ) is increasingly deployed as an antimalaria drug in Africa. We report the detection in Mali of Plasmodium falciparum infections carrying plasmepsin 2 duplications (associated with piperaquine resistance) in 7/65 recurrent infections within 2 months after DHA/PPQ treatment. These findings raise concerns about the long-term efficacy of DHA/PPQ treatment in Africa.

引用

页码：1591 / 1593

页数：3

共 50 条

[21] Treatment uptake by individuals infected with Plasmodium falciparum in rural Gambia, West Africa
von Seidlein, L
Clarke, S
Alexander, N
Manneh, F
Doherty, T
Pinder, M
Walraven, G
Greenwood, B
BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2002, 80 (10) : 790 - 796
[22] Assessment of Biological Role and Insight into Druggability of the Plasmodium falciparum Protease Plasmepsin V
Polino, Alexander J.
Nasamu, Armiyaw S.
Niles, Jacquin C.
Goldberg, Daniel E.
ACS INFECTIOUS DISEASES, 2020, 6 (04): : 738 - 746
[23] Expression and enzymatic characterization of the soluble recombinant plasmepsin I from Plasmodium falciparum
Xiao, Huogen
Tanaka, Takuji
Ogawa, Masahiro
Yada, Rickey Y.
PROTEIN ENGINEERING DESIGN & SELECTION, 2007, 20 (12): : 625 - 633
[24] Docking studies of binding of Plasmodium falciparum plasmepsin II to normal and sickle hemoglobin
Marguet, Sean
Waingeh, Victor
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
[25] Plasmodium falciparum with Multidrug Resistance 1 Gene Duplications, Senegal
Pascual, Aurelie
Fall, Becaye
Wurtz, Nathalie
Fall, Mansour
Camara, Cheikhou
Nakoulima, Aminata
Baret, Eric
Diatta, Bakary
Wade, Boubacar
Briolant, Sebastien
Pradines, Bruno
EMERGING INFECTIOUS DISEASES, 2013, 19 (05) : 814 - 815
[26] In vitro and in silico studies of naphthoquinones and peptidomimetics toward Plasmodium falciparum plasmepsin V
Sittikul, Pichamon
Songtawee, Napat
Kongkathip, Ngampong
Boonyalai, Nonlawat
BIOCHIMIE, 2018, 152 : 159 - 173
[27] In Silico and In Vitro Antimalarial Screening and Validation Targeting Plasmodium falciparum Plasmepsin V
Ji, Xin
Wang, Zhensheng
Chen, Qianqian
Li, Jingzhong
Wang, Heng
Wang, Zenglei
Yang, Lan
MOLECULES, 2022, 27 (09):
[28] Dietary flavonoids fisetin and myricetin: Dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II
Jin, Huangtao
Xu, Zhongyu
Cui, Kunqiang
Zhang, Tianshu
Lu, Weiqiang
Huang, Jin
FITOTERAPIA, 2014, 94 : 55 - 61
[29] Expression and Purification of Functionally Active Recombinant Plasmepsin 9 from Plasmodium falciparum
Olajuyigbe, Folasade M.
PROTEIN SCIENCE, 2014, 23 : 74 - 74
[30] Targeting the Plasmodium falciparum plasmepsin V by ligand-based virtual screening
Meissner, Kamila Anna
Kronenberger, Thales
Maltarollo, Vinicius Goncalves
Goulart Trossini, Gustavo Henrique
Wrenger, Carsten
CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 93 (03) : 300 - 312

← 1 2 3 4 5 →